Conference Proceedings

An oral, selective tyrosine kinase 2 (TYK2) inhibitor, BMS-986165, improves quality of life (QoL) in psoriasis (PsO): results from a Phase 2 study

Diamant Thaci, Kim Alexander Papp, Kenneth Gordon, Akimichi Morita, Melinda Gooderham, Peter Foley, Evo Alemao, Renata Kisa, Yedid Elbez, Haobo Ren, Subhashis Banerjee

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | WILEY | Published : 2020